首页> 外文学位 >Ligand selectivity: Binding at the protein-protein interface of Keap1 and NEMO.
【24h】

Ligand selectivity: Binding at the protein-protein interface of Keap1 and NEMO.

机译:配体选择性:在Keap1和NEMO的蛋白质-蛋白质界面处结合。

获取原文
获取原文并翻译 | 示例

摘要

This dissertation comprises identifying the structural determinants of binding selectivity as demonstrated in three systems.The first system involves the structure determination of Keap1-small molecule fragment complexes to locate binding surfaces. The second system involves the structural determination of a NEMO/IKKbeta complex to serve as a platform for future fragment binding validation studies. The third system involves the structural investigation of a bacterial phosphoglycosyltransferase found in Campylobacter concisus to find the active site. Keap1 binding of Nrf2 is a regulatory mechanism to inhibit the transcription factor activity of Nrf2 to upregulate Nucleoporin p62 (p62). Nucleoporin p62 is a regulator of tau protein aggregates in Alzheimer's disease. The determination of binding hot spots in the Keap1 active site could serve as a starting point for the development of inhibitors as a treatment method for Alzheimer's disease. To achieve this, I have developed a crystal form of Keap1 that allows for fragment-based study of binding in the active site via small molecule fragment screening and X-ray crystallography. Analysis of collected data has resulted in the solution of four structures, one containing a peptide fragment and three containing small molecule fragments that occupy a region of binding within the Keap1 active site, demonstrating the utility of the crystal form and affording information on binding hot spots.;Nuclear factor ?-light-chain enhancer of activated B cells (NF-kappaB) is a transcription factor and has been linked to cancer, inflammation, and immune dysfunction. The enzyme complex IkappaB kinase (IKK) is a regulator of NF-kappaB and consists of three subunits: IKK-alpha, IKK-beta, and NEMO. If NEMO activity is abrogated, IKK is unable to activate NF-kappaB, making it a promising therapeutic target. My research has found crystallization conditions and performed trials of phase determination on an N terminal IKKbeta-binding construct of NEMO containing previously uncharacterized regions of this protein.;Glycosylation is a commonly occurring post-translational modification that affects a number of processes including protein folding, trafficking, cell-cell interactions and host immune response. The phosphoglycosyl transferase PglC is an essential part of the Campylobacter glycosylation pathway and a possible antibacterial target. My research determined the crystallization conditions and has developed complexes and protein constructs for phase determination of this single-pass transmembrane protein and will in the future provide a platform for structure-based inhibition of this protein.
机译:本论文包括确定结合选择性的结构决定因素,如三个系统所示。第一个系统涉及确定Keap1-小分子片段复合物的结构以定位结合表面。第二个系统涉及NEMO / IKKbeta复合物的结构测定,以作为未来片段结合验证研究的平台。第三个系统涉及对结膜弯曲杆菌中发现的细菌磷酸糖基转移酶的结构研究,以发现活性位点。 Keap1与Nrf2的结合是一种调节机制,可抑制Nrf2的转录因子活性,从而上调Nucleoporin p62(p62)。 Nucleoporin p62是阿尔茨海默氏病中tau蛋白聚集体的调节剂。 Keap1活性位点结合热点的确定可以作为开发作为阿尔茨海默氏病治疗方法的抑制剂的起点。为实现此目的,我开发了Keap1的晶体形式,该形式可通过小分子片段筛选和X射线晶体学研究基于片段的活性位点结合。对收集到的数据进行分析后得出了四个结构的解决方案,一个结构包含一个肽片段,三个包含小分子片段,这些片段占据了Keap1活性位点内的结合区域,证明了该晶型的实用性并提供了有关结合热点的信息活化的B细胞的核因子β-轻链增强子(NF-κB)是一种转录因子,与癌症,炎症和免疫功能障碍有关。酶复合物IkappaB激酶(IKK)是NF-kappaB的调节剂,由三个亚基组成:IKK-alpha,IKK-beta和NEMO。如果取消NEMO活性,IKK将无法激活NF-κB,使其成为有希望的治疗靶标。我的研究发现了结晶条件,并在NEMO的N末端IKKbeta结合构建体上进行了相测定试验,该构建体包含该蛋白先前未表征的区域。糖基化是一种常见的翻译后修饰,影响许多过程,包括蛋白质折叠,运输,细胞间相互作用和宿主免疫反应。磷酸糖基转移酶PglC是弯曲杆菌糖基化途径的重要组成部分,并且可能是抗菌目标。我的研究确定了结晶条件,并开发了用于此单程跨膜蛋白相测定的复合物和蛋白构建体,并将在将来为基于结构抑制该蛋白提供平台。

著录项

  • 作者

    Lynch, Andrew John.;

  • 作者单位

    Boston University.;

  • 授予单位 Boston University.;
  • 学科 Biochemistry.;Biophysics.
  • 学位 Ph.D.
  • 年度 2016
  • 页码 163 p.
  • 总页数 163
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号